Revenue - InterCure Ltd (NASDAQ:INCR) - Alpha Spread
I

InterCure Ltd
NASDAQ:INCR

Watchlist Manager
InterCure Ltd
NASDAQ:INCR
Watchlist
Price: 1.86 USD Market Closed
Market Cap: 84.8m USD
Have any thoughts about
InterCure Ltd?
Write Note

InterCure Ltd
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

InterCure Ltd
Revenue Peer Comparison

Comparables:
TEVA
RDHL
SLGL
MDWD
R
REKA

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
I
InterCure Ltd
NASDAQ:INCR
Revenue
â‚Ş355.6m
CAGR 3-Years
76%
CAGR 5-Years
N/A
CAGR 10-Years
45%
Teva Pharmaceutical Industries Ltd
NYSE:TEVA
Revenue
$16.3B
CAGR 3-Years
0%
CAGR 5-Years
-1%
CAGR 10-Years
-2%
Redhill Biopharma Ltd
NASDAQ:RDHL
Revenue
$9.1m
CAGR 3-Years
-52%
CAGR 5-Years
6%
CAGR 10-Years
3%
Sol Gel Technologies Ltd
NASDAQ:SLGL
Revenue
$6.6m
CAGR 3-Years
4%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Mediwound Ltd
NASDAQ:MDWD
Revenue
$20.1m
CAGR 3-Years
-7%
CAGR 5-Years
-3%
CAGR 10-Years
72%
R
Rekah Pharmaceutical Industry Ltd
TASE:REKA
Revenue
â‚Ş332.3m
CAGR 3-Years
8%
CAGR 5-Years
11%
CAGR 10-Years
2%

See Also

What is InterCure Ltd's Revenue?
Revenue
355.6m ILS

Based on the financial report for Dec 31, 2023, InterCure Ltd's Revenue amounts to 355.6m ILS.

What is InterCure Ltd's Revenue growth rate?
Revenue CAGR 10Y
45%

Over the last year, the Revenue growth was -9%. The average annual Revenue growth rates for InterCure Ltd have been 76% over the past three years , and 45% over the past ten years .

Back to Top